The latent dementia phenotype δ is associated with cerebrospinal fluid biomarkers of Alzheimer's disease and predicts conversion to dementia in subjects with mild cognitive impairment

Journal of Alzheimer's Disease

Volumn 49, Issue 2, 2015, Pages 547-560

  Koppara, Alexander ^a,b   Wolfsgruber, Steffen ^a,b   Kleineidam, Luca ^a,b   Schmidtke, Klaus ^c   Frölich, Lutz ^d   Kurz, Alexander ^e   Schulz, Stefanie ^f   Hampel, Harald ^h   Heuser, Isabella ⁱ   Peters, Oliver ⁱ   Reischies, Friedel M ⁱ   Jahn, Holger ^j   Luckhaus, Christian ^k   Hüll, Michael ^l   Gertz, Hermann Josef ^m   Schröder, Johannes ⁿ   Pantel, Johannes ^o   Rienhoff, Otto ^g   Rüther, Eckart ^g   Henn, Fritz ^p   Wiltfang, Jens ^g   Maier, Wolfgang ^a,b   Jessen, Frank ^a,b,r   Kornhuber, Johannes ^q   Wagner, Michael ^a,b   more..

^a UNIVERSITY OF BONN   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c Ortenau Klinikum   (Germany)

^d CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^g UNIVERSITY OF GÖTTINGEN   (Germany)

^h SORBONNE UNIVERSITÉ   (France)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j UNIVERSITY OF HAMBURG   (Germany)

^k HEINRICH HEINE UNIVERSITY   (Germany)

^l UNIVERSITY OF FREIBURG   (Germany)

^m UNIVERSITY OF LEIPZIG   (Germany)

ⁿ UNIVERSITY OF HEIDELBERG   (Germany)

^o GOETHE UNIVERSITY   (Germany)

^p MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^q UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^r UNIVERSITY OF COLOGNE   (Germany)

more..

Author keywords

CSF AD biomarker signature; delta model; incident dementia; mild cognitive impairment

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; COMPARATIVE STUDY; DEMENTIA; DIFFUSE LEWY BODY DISEASE; FEMALE; FOLLOW UP; FRONTOTEMPORAL DEMENTIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MIXED DEPRESSION AND DEMENTIA; NEUROPSYCHOLOGICAL TEST; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; DAILY LIFE ACTIVITY; DISEASE COURSE; LONGITUDINAL STUDY; MENTAL HEALTH; MIDDLE AGED; PREDICTIVE VALUE; PSYCHOLOGY; RETROSPECTIVE STUDY; STATISTICAL MODEL;

ACTIVITIES OF DAILY LIVING; AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; DEMENTIA; DISEASE PROGRESSION; FEMALE; HUMANS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TAU PROTEINS;

EID: 84948662392     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150257     Document Type: Article

References (56)

1. U.S. Department of Health and Human Services (2013) Guidance for Industry Alzheimer's Disease: Developing Drugs for the Treatment of Early Stage Disease.
2. Black R, Greenberg B, Ryan J, Michael, Posner H, Seeburger J, Amatniek J, Resnick M, Mohs R, Miller DS, Saumier D, Carrillo MC, Stern Y (2009) Scales as outcome measures for Alzheimer's disease. Alzheimers Dement 5, 324-339.
3. Raghavan N, Samtani MN, Farnum M, Yang E, Novak G, Grundman M, Narayan V, DiBernardo A (2013) The ADASCog revisited: Novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials. Alzheimers Dement 9, S21-S31.
4. Skinner J, Carvalho JO, Potter GG, Thames A, Zelinski E, Crane PK, Gibbons LE (2012) The Alzheimer's Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): An expansion of the ADAS-Cog to improve responsiveness in MCI. Brain Imaging Behav 6, 489-501.
5. Royall DR, Palmer RF, O'Bryant SE (2012) Validation of a latent variable representing the dementing process. J Alzheimers Dis 30, 639-649.
6. Royall DR, Palmer RF (2012) Getting past 'g': Testing a new model of dementing processes in persons without dementia. J Neuropsychiatry Clin Neurosci 24, 37-46.
7. Royall DR, Matsuoka T, Palmer RF, Kato Y, Taniguchi S, Ogawa M, Fujimoto H, Okamura A, Shibata K, Nakamura K, Nakaaki S, Koumi H, Mimura M, Fukui K, Narumoto J (2015) Greater than the sum of its parts: ä improves upon a battery's diagnostic performance. Neuropsychology 29, 683-692.
8. Gavett BE, Vudy V, Jeffrey M, John SE, Gurnani AS, Adams JW (2015) The δ latent dementia phenotype in the uniform data set: Cross-validation and extension. Neuropsychology 29, 344-352.
9. Royall DR, Palmer RF (2013) Validation of a latent construct for dementia case-finding in Mexican-Americans. J Alzheimers Dis 37, 89-97.
10. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL (1982) A new clinical scale for the staging of dementia. Br J Psychiatry 140, 566-572.
11. Palmer RF, Royall DR (2015) Future dementia severity is almost entirely explained by the latent variable ä's intercept and slope. J Alzheimers Dis 49, 521-529.
12. Royall DR, Palmer RF (2014) Does ethnicity moderate dementia's biomarkers? Neurobiol Aging 35, 336-344.
13. Royall DR, Palmer RF (2015) Ethnicity moderates dementia's biomarkers. J Alzheimers Dis 43, 275-287.
14. Royall DR, Palmer RF (2014) 'Executive functions' cannot be distinguished from general intelligence: Two variations on a single theme within a symphony of latent variance. Front Behav Neurosci 8, 369.
15. Buckner RL, Sepulcre J, Talukdar T, Krienen FM, Liu H, Hedden T, Andrews-Hanna JR, Sperling RA, Johnson KA (2009) Cortical hubs revealed by intrinsic functional connectivity: Mapping, assessment of stability, and relation to Alzheimer's disease. J Neurosci 29, 1860-1873.
16. Royall DR, Palmer RF, Vidoni ED, Honea RA, Burns JM (2012) The default mode network and related right hemisphere structures may be the key substrates of dementia. J Alzheimers Dis 32, 467-478.
17. McArdle J, Grimm K (2010) Five steps in latent curve and latent change score modeling with longitudinal data. In: Longitudinal Research with Latent Variables, van Montfort K, Oud JH, Satorra A, eds., Springer Berlin Heidelberg, pp. 245-273.
18. Kornhuber J, Schmidtke K, Frolich L, Perneczky R, Wolf S, Hampel H, Jessen F, Heuser I, Peters O, Weih M, Jahn H, Luckhaus C, Hull M, Gertz H, Schroder J, Pantel J, Rienhoff O, Seuchter SA, Ruther E, Henn F, Maier W, Wiltfang J (2009) Early and differential diagnosis of dementia and mild cognitive impairment. Dement Geriatr Cogn Disord 27, 404-417.
19. Lewczuk P, Kornhuber J, Wiltfang J (2006) The German Competence Net Dementias: Standard operating procedures for the neurochemical dementia diagnostics. J Neural Transm 113, 1075-1080.
20. Lewczuk P, Esselmann H, Otto M, Maler JM, Henkel AW, Henkel MK, Eikenberg O, Antz C, Krause W, Reulbach U, Kornhuber J, Wiltfang J (2004) Neurochemical diagnosis of Alzheimer's dementia by CSF A-42, A-42/A-40 ratio and total tau. Neurobiol Aging 25, 273-281.
21. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, DeDeyn PP, Bancher C, Cras P, Wiltfang J, Mehta PD, Iqbal K, Pottel H, Vanmechelen E, Vanderstichele H (1999) Improved discrimination of AD patients using beta-Amyloid(1-42) and tau levels in CSF. Neurology 52, 1555-1562.
22. Wolfsgruber S, Jessen F, Koppara A, Kleineidam L, SchmidtkeK, Frolich L, Kurz A, Schulz S, Hampel H, Heuser I, Peters O, Reischies FM, Jahn H, Luckhaus C, Hull M, Gertz HJ, Schroder J, Pantel J, Rienhoff O, Ruther E, Henn F, Wiltfang J, Maier W, Kornhuber J, Wagner M (2015) Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI. Neurology 84, 1261-1268.
23. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, Mellits ED, Clark C (1989) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 39, 1159-1165.
24. Reitan RM (1958) Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills 8, 271-276.
25. Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
26. Chandler MJ, Lacritz LH, Hynan LS, Barnard HD, Allen G, Deschner M, Weiner MF, Cullum CM (2005) A total score for the CERAD neuropsychological battery. Neurology 65, 102-106.
27. Paajanen T, Hanninen T, Tunnard C, Hallikainen M, Mecocci P, Sobow T, Tsolaki M, Vellas B, Lovestone S, Soininen H (2014) CERAD neuropsychological compound scores are accurate in detecting prodromal alzheimer's disease: A prospective addneuromed study. J Alzheimers Dis 39, 679-690.
28. Wolfsgruber S, Jessen F, Wiese B, Stein J, Bickel H, Mosch E, Weyerer S, Werle J, Pentzek M, Fuchs A (2014) The CERAD neuropsychological assessment battery total score detects and predicts Alzheimer disease dementia with high diagnostic accuracy. Am J Geriatr Psychiatry 22, 1017-1028.
29. Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer's disease. Am J Psychiatry 141, 1356-1364.
30. Hindmarch I, Lehfeld H, Jongh P, de, Erzigkeit H (1998) The Bayer activities of daily living scale (B-ADL). Dement Geriatr Cogn Disord 9, 20-26.
31. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 270-279.
32. Wagner M, Wolf S, Reischies FM, Daerr M, Wolfsgruber S, Jessen F, Popp J, Maier W, Hull M, Frolich L, Hampel H, Perneczky R, Peters O, Jahn H, Luckhaus C, Gertz H, Schroder J, Pantel J, Lewczuk P, Kornhuber J, Wiltfang J (2012) Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease. Neurology 78, 379-386.
33. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund L, Nordberg A, Backman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, Leon M, de, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC (2004) Mild cognitive impairment-beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. J Intern Med 256, 240-246.
34. A1993) The ICD-10 Classification of mental and behavioural disorders: Diagnostic criteria for research. World Health Organization, http://www.who.int/classifications/icd/en/GR NBOOK.pdf
35. Jorm AF, Jacomb PA (1989) The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): Sociodemographic correlates, reliability, validity and some norms. Psychol Med 19, 1015-1022.
36. Kertesz A, Nadkarni N, DavidsonW, ThomasAW(2000) The Frontal Behavioral Inventory in the differential diagnosis of frontotemporal dementia. J Int Neuropsychol Soc 6, 460-468.
37. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
38. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A (1993) Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43, 250-260.
39. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF (1998) Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology 51, 1546-1554.
40. Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol 56, 33-39.
41. Vonsattel JP, DiFiglia M (1998) Huntington disease. J Neuropathol Exp Neurol 57, 369-384.
42. Litvan I (1997) The clinical and pathologic hallmarks of progressive supranuclear palsy. Curr Opin Neurol 10, 346-350.
43. Litvan I, Grimes DA, Lang AE, Jankovic J, McKee A, Verny M, Jellinger K, Chaudhuri KR, Pearce RK (1999) Clinical features differentiating patients with postmortem confirmed progressive supranuclear palsy and corticobasal degeneration. J Neurol 246(Suppl 2), II1-II5.
44. Muthen LK, Muthen BO (2012) Mplus User's Guide (7. AuA .). Muthen & Muthen, Los Angeles.
45. Thomson GH (1934) The meaning of 'i'in the estimate of 'g'. Br J Psychol Gen Sect 25, 92-99.
46. Muthen BO (2004) 1998-2004. Mplus technical appendices. Muthen & Muthen, Los Angeles.
47. Grice JW (2001) Computing and evaluating factor scores. Psychol Method 6, 430.
48. Muthen BO, Hsu JY (1993) Selection and predictive validity with latent variable structures. Br J Math Stat Psychol 46, 255-271.
49. Browne MW, Cudeck R, Bollen KA, Long JS (1993) Alternative ways of assessing model fit. Sage Focus Edition 154, 136.
50. Bentler P, Comparative fit indexes in structural models. Psychol Bull 107, 238-246.
51. Bollen KA, Long JS (1993) Testing structural equation models, Sage.
52. Hosmer Jr, David W, Lemeshow S, Sturdivant RX (2013) Applied Logistic Regression, John Wiley & Sons.
53. DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 44, 837-845.
54. Palmqvist S, Hertze J, Minthon L, Wattmo C, Zetterberg H, Blennow K, Londos E, Hansson O (2012) Comparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer's disease in mild cognitive impairment: Six-year follow-up study. PloS One 7, e38639.
55. Auriacombe S, Helmer C, Amieva H, Berr C, Dubois B, Dartigues J (2010) Validity of the free and cued selective reminding test in predicting dementia: The 3C Study. Neurology 74, 1760-1767.
56. Rentz DM, Parra Rodriguez, Mario A, Amariglio R, Stern Y, Sperling R, Ferris S (2013) Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer's disease: A selective review. Alzheimers Res Ther 5, 58.